Background: Testosterone deficiency (TD, total testosterone ≤350 ng/dL
| INTRODUCTION
Testosterone is linked to many physiologic effects, including improved sexual function, physical performance, muscle strength, lean body mass and cognitive function. 1, 2 Low levels of testosterone are associated with cardiovascular diseases, 3 cancer 4 and all-cause mortality. ]). [6] [7] [8] In the United States, it has been reported that there are approximately 2.4 million men in age groups 40-69 years old with TD. 9 ,10 Yet, a greater concern is the projection that by 2025 approximately 6.5 million American men aged 30 to 80 will have TD.
8
In parallel to TD, the obesity epidemic has worsened affecting over 30% of men in the United States (US). 11 Similar to TD, obesity has also been linked to cardiovascular diseases, 12 cancer 13 and all-cause mortality.
14 Interestingly, there is inverse relationship between high levels of testosterone and body fatness (measured by body mass index [BMI] ≥30 kg/m 2 , waist circumference ≥102 cm, percentage of body fat ≥25% or increased adipose tissue), which has been shown to be consistent in cross-sectional studies, 15 prospective cohort studies 16 and systematic reviews and meta-analyses. 17 This relationship has been shown to be bidirectional; that is, low levels of testosterone increase the risk of body fatness, and body fatness increases the risk of low levels of testosterone. 18 However, the sequelae of the co-occurrence of TD and body fatness on the risk of health outcomes remain undetermined. Therefore, we investigated whether the co-occurrence of TD and overall obesity (BMI ≥30 kg/m 2 ), and abdominal obesity (waist circumference [WC] ≥102 cm), is associated with an increased risk of all-cause mortality in a representative sample of US men.
| SUBJECTS AND METHODS

| Study population
The National Health and Nutrition Examination Survey (NHANES)
is a programme of studies undertaken by the National Center for
Health Statistics (NCHS) of the US Centers for Disease Control and
Prevention (CDC) to assess the health and nutritional status of adults and children in the United States. NHANES uses a multistage, stratified and clustered probability sampling strategy in which MexicanAmericans, non-Hispanic Blacks and the elderly are oversampled to ensure adequate sample size and to represent the total US civilian, noninstitutionalized population. 19 The NHANES includes an interview and an examination component that includes blood collection.
Investigators are allowed to access surplus sera for approved studies.
Details of the survey design, methods and data collections are available on the NHANES website (https://www.cdc.gov/nchs/nhanes/ index.htm. Accessed 30 Jan. 2017 ).
This study included data from male participants in the 1999- Male participants younger than 20 years were not included in this study (n = 529). We excluded participants with a self-reported history of cardiovascular disease or prostate cancer because certain treatments may affect hormone levels (n = 18). In addition, we excluded 22 men for having missing sex hormone measurements, and additional 6 men were excluded for having extreme hormone measurements, 42 missing data of BMI and waist circumference, 2 missing linkages to mortality and 105 missing information on covariates.
The following threshold points were used to determine extreme measurements based on a visual inspection of the distribution: testosterone = 5000 ng/dL (n = 1), oestradiol = 360 pg/mL (n = 1) and sex hormone binding globulin (SHBG) >170 nmol L −1 (n = 4), leaving a final sample of 948 men. The NHANES programme is approved by 
| Assessment of covariates
Age, race/ethnicity, cigarette smoking, alcohol consumption, diabetes and physical activity during the past 30 days were self-reported during the NHANES interviews. Waist circumference (WC) at the iliac crest, height and weight were measured during the examination. 
| Statistical analysis
The formed to examine the differences in survival curves between groups of TD and body fatness. We used Cox proportional hazards regression to estimate the age-race/ethnicity and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality associated independently with TD, overall obesity and abdominal obesity, and subsequently the combination of TD with overall or abdominal obesity. Multivariable models included SHBG, oestradiol, age, race/ethnicity, smoking status, alcohol consumption, diabetes and physical activity. Because total testosterone and oestradiol have been previously correlated 25 and SHBG is a major carrier of testosterone in circulation, they were included in the multivariable models. Tests for interaction were carried out using the ordinal sex steroid hormone, ordinal or binary variables for overall or abdominal obesity and their product terms. The statistical significance of the interaction terms was evaluated by the Wald test. All P-values were two-sided; .05 was considered the cut-off for statistical significance;
and all analyses were performed using survey data analysis commands in STATA version 10 (College Station, TX) to account for the complex NHANES sample survey design.
| RESULTS
The distribution of baseline characteristics in the study population after applying sample weights is reported in Table 1 . Of the 948 men included in this study, the mean age was 48 years old, and the majority of the participants were non-Hispanic white (n = 488; 51.5%).
The mean BMI was 27.80 kg/m Sampling weights were applied. Table 2 shows the characteristics of the study population by mortality status. A median follow-up of 9.5 years was reported in this study of 142 (15%) identified deaths and 806 alive men. As expected, men who died were older had larger waist circumference and a higher prevalence of abdominal obesity (49.30%). In addition, these men were more likely to have a low mean level of total testosterone, to be former smokers (50.00%) and had a higher frequency of TD (38.73%), TDcft (66.90%), diabetes (26.80%), consumed less alcohol (13.04%) and performed less vigorous physical activity (31.6%). In addition, the frequency of the co-occurrence of TD and overall obesity (16.9%) or abdominal obesity (26.10%) was greater among men who died.
Survey-weighted adjusted HRs and 95% CIs using multivariable
Cox proportional hazards models are presented in co-occurrence of TD and overall obesity with men without TD and no overall obesity (HR = 2.90; 95% CI = 0.92-9.60).
T A B L E 2 Continued T A B L E 2 Study population characteristics based on mortality status
We also conducted multivariable analysis for the association between TDcft and mortality, including the co-occurrence of TDcft with overall obesity and abdominal obesity (Table 3 ). There was approximately a 3-fold increased risk of death among men with TDcft compared with those men without TDcft (HR = 2.99; 95% CI = 1.26-7.10).
Similar to the interaction analysis of TD (total testosterone) and body fatness, the interaction between TDcft and overall obesity and abdominal obesity was not associated with risk of death, P interaction = .56
and P interaction = .93, respectively. Yet, compared with men without TDcft and no overall obesity, the co-occurrence of TDcft and overall obesity increased the risk of death more than 3-fold (HR = 3.80; 95% CI = 1.12-8.71). Furthermore, compared with those without TDcft and no abdominal obesity, men with TDcft and abdominal obesity had 3.56 times higher risk of death (HR = 3.56, 95% CI = 1.27-10.00). Figure 1 shows higher cumulative overall mortality among men with TD (P-value for log-rank test ≤.01) in Kaplan-Meir survival curves.
Figures 2 and 3 show that men with co-occurrence of TD and overall obesity and abdominal obesity had significantly poor survival than men without TD and no overall obesity or abdominal obesity (P-value for log-rank test ≤.01, both). In sensitivity analysis, we excluded deaths T A B L E 3 Hazard ratios and 95% Confidence Intervals for all-cause mortality by co-occurrence of TD (total testosterone and calculated free testosterone) and measures of adiposity in NHANES 1999-2011 the first 12 months to reduce the probability of reverse causality; however, the results remained very similar (data were not shown). In with TDcft and with the co-occurrence of TDcft and overall obesity and abdominal obesity (P-value for log-rank test ≤.01, each).
| DISCUSSION
These results show that TD, defined by low levels of either total testosterone or free testosterone, was associated with increased risk of death in multivariable analyses. On the other hand, we did not identify a nominally significant association between overall or abdominal obesity and mortality status. The interaction between TD (either total testosterone or calculated free testosterone) and overall obesity and abdominal obesity with mortality was not statistically significant.
However, compared with men without TD and no abdominal obesity, the co-occurrence of TD and abdominal obesity increased the risk of death. In contrast, the co-occurrence of TD and overall obesity was not significantly associated with mortality. Interestingly, TDcft was linked with an increased risk of death as well. In addition, the co-occurrence of TDcft and overall or abdominal obesity compared with their respective reference groups were independently and significantly associated with risk of death.
A number of studies have suggested a link between low levels of testosterone and risk of mortality, 5, 26, 27 and another body of literature has identified similar findings between obesity and mortality. 14 Yet, the relationship between testosterone and obesity has been shown to be bidirectional with an unknown causal direction. 18 Furthermore, another emerging body of literature that supports the link between low testosterone and obesity is the increasing use of testosterone therapy (TTh). 28 Due to the obesity epidemic, it has been suggested that the prevalence of TD has increased and consequently its treatment, TTh. 28, 29 TTh has increased dramatically in the last decade from 0.81% in 2001 to 2.9% in 2011. 30 Interestingly, Neto et al. 31 conducted a systematic review and meta-analysis of 8 randomized placebo-controlled trials of use of TTh in men over 60 years old with serum testosterone ≤550 ng/mL and reported a significant increase in lean mass and decrease in fat mass. Moreover, large comprehensive meta-analyses of 32 observational studies (ie studies other than randomized controlled trials) of a total of 4513 patients by Corona et al. 32 reported that the use of TTh was associated with weight loss, reduced BMI, increased lean mass and reduced fat mass. Similarly, it is important to note that weight loss has also positive effects on increasing levels of testosterone. 16 Therefore, the sequelae of the co-occurrence of TD and body fatness on the risk of mortality warrant further investigation.
Some aspects of our prospective analysis merit discussion. First, we did not find an increased risk of mortality for overall obesity (BMI ≥30 kg/m 2 ). However, in previous NHANES studies, the associations of overweight (25 ≤ BMI ≤ 29.99) and overall obesity (BMI ≥30 kg/m 2 ) with mortality were reported in opposite directions; 33 overweight reduced the risk of mortality, but obesity increased it.
Due to small sample size in the TD and overall obesity categories, we only dichotomized overall obesity into ≥30 kg/m 2 . Therefore, this could have played a role in the lack of statistical association of overall obesity in our study. Similarly, Kuk et al. 34 Third, whether total testosterone or free testosterone is a better predictor of TD is a matter of debate and out of the scope of this investigation. 21 However, a number of studies have reported disparities in the association of total testosterone and free testosterone with body fatness, diabetes and weight loss. 15, 29 Therefore, our findings in the association of the co-occurrence of TD (total testosterone or free testosterone) and body fatness (overall obesity and abdominal obesity) with mortality reflect those disparities from previous studies. Finally, although the relationship between TD and body fatness is hypothesized to be bidirectional, there is still an unknown causal direction; therefore, it is suggested that future studies may continue focusing on the co-occurrence of TD and body fatness and their sequelae on health outcomes.
Our study has a number of strengths. NHANES is a programme of studies that is representative of the civilian noninstitutionalized US population, which aids in the generalizability of these results. In addition, NHANES follows a rigorous protocol with extensive quality control procedures for the collection of the exposures, outcome of interest and potential confounding factors analysed and adjusted in this study. We also mutually adjusted testosterone, SHB and oestradiol. Despite these strengths, the current study has several limitations, which may influence interpretation of these results. First, we relied on a single measurement of sex steroid hormones. Second, measurement of testosterone was obtained with electrochemiluminescence immunoassays, and not HPLC tandem mass spectrophotometry that has been recommended by some investigators. Third, measurements of BMI and WC are surrogate markers and may not fully or precisely capture the total amount of body fat or the location of excess body fat.
Fourth, the small sample size in the categories of the co-occurrence of TD and body fatness possibly limited the power to detect associations.
Therefore, we could not further examine the role of the co-occurrence of TD and body fatness in other specific causes of mortality, cardiovascular or cancer. Although we adjusted for several potential confounders, there is still the possibility of unmeasured confounding from additional unmeasured factors. However, due to our detailed adjustment for confounders, it is unlikely these would fully account for the observed findings.
In summary, the results of this study confirm and extend the observation that men with TD are at increased risk for all-cause mortality, with the additional observation that the co-occurrence of TD with abdominal obesity increases this mortality risk. In contrast to abdominal obesity, overall obesity was not associated with increased mortality risk in men with TD. Future studies with larger sample size for the co-occurrence of TD and abdominal obesity are warranted to confirm these findings.
ORCID
D.S. Lopez
http://orcid.org/0000-0002-2321-0372
